News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Helix Acquisition Corp. III (NASDAQ: HLXC) has filed its Form 10-Q for the quarter ending June 30, 2026, detailing financial results post its January 2026 IPO. The report highlights a trust account balance of $175,054,966, net income of $1,334,048 for Q2 2026, and a …
Farallon Capital Management, L.L.C., and its affiliated investment partnerships, the Farallon Funds, have disclosed a beneficial ownership of 13,989,010 shares of Exelixis, Inc. (EXEL). This stake represents 5.6% of Exelixis' outstanding common stock and has an approximate net investment cost of $308,124,978. The information …
Exelixis (EXEL) reported its Q2 2026 earnings, with total revenues reaching $628.7 million, a 10.6% increase year-over-year, driven by cabozantinib sales. The company updated its full-year 2026 revenue guidance downwards due to a more gradual sales ramp in the neuroendocrine tumor indication but reduced …
Annex Advisory Services LLC has acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL), purchasing 25,918 shares valued at approximately $1.41 million during the second quarter. This investment comes as Exelixis reported strong quarterly earnings, surpassing EPS expectations, though revenue slightly missed analyst estimates. Despite …
Argus has lowered its target price for Exelixis Inc. (EXEL) to $56.00, while the current price stands at $50.44. Exelixis is a biopharmaceutical company focused on discovering, developing, and commercializing cancer treatments.
Telix Pharmaceuticals reported its strongest quarterly revenue to date, reaching US$247 million in Q2 2026, driven by its Precision Medicine division. The company projects its total 2026 revenue plus other income to exceed US$1 billion, bolstered by a US$40 million payment from a new …
Exelixis director Mary Beckerle sold 9,812 shares of the company's common stock for over $526,000, executed under a Rule 10b5-1 trading plan. This transaction leaves her with 16,079 beneficially owned shares, including RSUs. The sale occurred as Exelixis's stock saw a recent decline but …
Exelixis (NASDAQ:EXEL) Director Mary Beckerle sold 9,812 shares of company stock, valued at $526,511.92, under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced her ownership by 37.9% to 16,079 shares. The biotechnology company recently reported strong quarterly earnings, beating analyst estimates with $0.91 …
Exelixis director Mary C. Beckerle sold 9,812 shares of common stock on August 10, 2026, at a weighted average price of $53.66 per share, under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Beckerle's holdings consist of 16,079 shares, which are to be …
Helix Energy Solutions Group (HLX) reported a return to profitability in Q2 2026 with sales of US$304.02 million and net income of US$22.72 million, a significant improvement from a net loss in the prior year. This financial turnaround is supported by a forecasted US$1.4 …
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have disclosed a beneficial ownership of 11,023,943 shares of Exelixis, Inc. common stock, representing 4.39% of the class. The filing indicates shared voting power over 10,935,221 shares and shared dispositive power over all 11,023,943 …
Helix (HLX) has revised its 2025 Form 10-K disclosures to present Helix Alliance as discontinued operations following its sale on May 1, 2026. This recast was necessary because Helix's S-4, filed on June 4, 2026, incorporates prior periods into an active registration statement. The …
Helix Energy Solutions Group, Inc. has revised its 2025 Annual Report on Form 10-K to reclassify its Shallow Water Abandonment segment as discontinued operations following the sale of Helix Alliance. This change, which was initially reflected in their Q2 2026 report, is required due …
This article reports that Helix Energy Solutions Group Inc. filed a Form 8K on August 11. It briefly mentions the company's stock performance (HLX +1.90%). The content is primarily a placeholder for the filing announcement rather than a detailed analysis of the Form 8K.
SueWallSt is investigating potential securities claims against Exelixis (NASDAQ: EXEL) following a reduction and narrowing of its full-year 2026 revenue guidance. The company's shares declined after it cited a slower-than-expected ramp in its neuroendocrine-tumor business, contradicting earlier reiterations of its financial outlook. Shareholders who …
This article highlights three growth stocks with high insider ownership: Predictive Discovery (ASX:PDI), Telix Pharmaceuticals (ASX:TLX), and Lindian Resources (ASX:LIN). It discusses their current financial situations, growth prospects, and associated risks, suggesting they are candidates for further investor research. The piece emphasizes looking for …
Levi & Korsinsky, LLP has announced an investigation into Exelixis (EXEL) after the company reiterated its full-year 2026 financial guidance on May 5, 2026, only to lower and narrow its revenue outlook weeks later, causing a stock decline. The investigation focuses on whether Exelixis …
Search by ticker symbol or company name and select a result to open its chart.